Patrick Spencer, RN, OCN provides important points to cover when counseling a patient with multiple myeloma receiving treatment with daratumumab.
Patrick Spencer, RN, OCN, of Mount Sinai Medical Center, provides some important points to cover when counseling a patient with multiple myeloma receiving treatment with daratumumab.
The first day especially requires long hours of infusion. Spencer also recommends that the patient bring a caregiver with them. There can be infusion-related reactions that a patient might not normally report, such as a runny nose or itchy throat. If patients are prepared, however, and know to inform their clinicians, they can receive the proper medication to prevent such reactions from becoming severe.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.